Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > 60% of the road = 270-days
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(237)
•••
Comment by Infinityon Jul 15, 2022 7:39am
165 Views
Post# 34826346

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:60% of the road = 270-days

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:60% of the road = 270-daysCancer Slayer,  Dilution to raise money would be an acceptable option.  However, prior to raising the money by PP or what ever means, I would like to see some positive news reports.  I believe, the management likes to keep things very quiet, even tend to under play positive news for reasons that is known only to them.  I for one can not wait till Roger gets back from the Penalty box in Februrary, 2023.   Time to become more vocal about our achievements so far.  I have not seen much from the newly hired investor relations co-ordinator either.  The TLT twitter account has not been all that active with cancer research news or any news related to our business... This stock, like many other small caps, will gain momentum based on news.  I would think it would be prudent to go in for up beat news first, hopefully raise the selling price to a very modest $1 before resorting to any fund raising...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities